‘Revolutionary' device transforms maternal health

‘Revolutionary’ device transforms maternal health

Date of Report 24/08/2021
ASX: HMD

Price A$0.20

52 Week Range: A$0.086 - 0.305

Market Cap: A$31.89m

Sector: Health Care Equipment & Services

Every second week we invite a leading fund manager to present at The Insider: Meet the Fund Manager. Shaun Cartwright from Viriathus Australia selected HeraMED Limited (ASX: HMD) as one of his 3 favourite stocks, as the demand for telehealth grows.

March 26th, 2021

June 9th, 2021

The Insider: Meet the Fund Manager sessions are a great way to hear directly from leading funds managers. They share their approach to investing, favourite companies and their market view for the year ahead.

The Insider: Meet the CEO sessions feature a selection of company leaders who provide a succinct overview of big things their companies are doing. 

Telehealth use has grown to 38 times its pre-pandemic levels and is expected to become embedded into traditional healthcare systems as patients embrace its convenience.

Among the growing user base are expectant mothers, many of whom are turning to ASX-listed company HeraMED’s revolutionary devices to bring maternal health care into their homes.

Gone are the days of expensive and exhausting visits to the doctor during a pregnancy. HeraMED’s device allows pregnant mothers to monitor the health of their unborn baby throughout the whole pregnancy by using a subscription-based phone app. If there are any irregularities, mothers can immediately get in touch with their doctor. 

“Now that everyone has got comfortable with using telehealth technology, and witnessed its benefits, there’s no going back. This obviously creates a significant tailwind to our business model and unique offerings,” said David Groberman, CEO and Co-Founder of HeraMED.

The potential of HeraMED to transform maternal healthcare has recently caught the eye of professional investors too.

“It’s incredibly revolutionary,” said Viriathus Capital’s Shaun Cartwright who identified HeraMED as one of his favourite stocks for a post-pandemic world earlier this year.

Having hit the US$111 billion US maternal healthcare market Mr Cartwright noted that with its current market cap, global potential and FDA approval, HeraMED has a “huge amount of upside.”

“This is another one to put on the watch list and keep an eye on,” he concluded.

Click here to view more videos from Shaun Cartwright’s ‘Meet the Fund Manager’ session, or click here to view the full ‘ The Insider: Meet the CEOs’.

 

The CEO’s of all the companies chosen as Fund Manager favourite stocks are invited to present at our Meet the CEO series. Reach does not assume responsibility for the accuracy or completeness of any information provided, and the views expressed are not reflective of Reach Markets position.

Any advice contained within this presentation is general advice and does not consider your personal circumstance, you should consider whether it’s appropriate for you.

The information we are giving you is for educational purposes only. “Investing is about understanding your risk” and every time you invest in the share market there is a risk of loss.

Meet the Fund Manager

Upcoming Session

Meet the Manager

Get access to some of Australia’s leading fund managers who share their 3 favourite stocks, investment approach and insights on the market.

Each session includes:

  • 3 favourite stock opportunities
  • Market views for the year ahead
  • Investment strategy and approaches

This is a live and interactive session, where you get the rare opportunity for Q&A with a fund manager. Spots are limited – book now to access this FREE event.

Book into the next session

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.

The CEOs of all the companies chosen as Fund Manager favourite stocks are invited to present at our Meet the CEO series. Reach does not assume responsibility for the accuracy or completeness of any information provided, and the views expressed are not reflective of Reach Markets position.
Any advice contained within this presentation is general advice and does not consider your personal circumstance, you should consider whether it’s appropriate for you.
The information we are giving you is for educational purposes only. “Investing is about understanding your risk” and every time you invest in the share market there is a risk of loss.